[F]FSPG-PET Provides an Early Marker of Radiotherapy Response in Head and Neck Squamous Cell Cancer

Overview

Journal Npj Imaging

Date 2024 Aug 12

PMID 39132311

Authors

Khrishanthne Sambasivan

Will E Tyrrell

Rizwan Farooq

Jenasee Mynerich

Richard S Edwards

Muhammet Tanc

Teresa Guerrero Urbano

Timothy H Witney

Affiliations

Soon will be listed here.

Abstract

The ability to image early treatment response to radiotherapy in head and neck squamous cell carcinoma (HNSCC) will enable the identification of radioresistant tumor volumes suitable for treatment intensification. Here, we propose the system x radiotracer (4)-4-(3-[F]fluoropropyl)-L-glutamate ([F]FSPG) as a non-invasive method to monitor radiation response in HNSCC. We assessed temporal changes in cell death, antioxidant status, and [F]FSPG retention following a single dose of 10 Gy irradiation in FaDU HNSCC cells. Next, using a fractionated course of radiotherapy, we assessed tumor volume changes and performed [F]FSPG-PET imaging in FaDU-bearing mouse xenografts, followed by ex vivo response assessment. In cells, 10 Gy irradiation reduced [F]FSPG retention, coinciding with the induction of apoptosis and the production of reactive oxygen species. In vivo, [F]FSPG tumor retention was halved seven days after the start of treatment, which preceded radiotherapy-induced tumor shrinkage, thereby confirming [F]FSPG-PET as an early and sensitive marker of radiation response.

Citing Articles

Compact and cGMP-compliant automated synthesis of [F]FSPG on the Trasis AllinOne™.

Farooq R, Gendron T, Edwards R, Witney T EJNMMI Radiopharm Chem. 2025; 10(1):2.

PMID: 39821860 PMC: 11748660. DOI: 10.1186/s41181-024-00322-7.

Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography.

Greenwood H, Barber A, Edwards R, Tyrrell W, George M, Dos Santos S Nat Commun. 2024; 15(1):10484.

PMID: 39690148 PMC: 11652680. DOI: 10.1038/s41467-024-54852-4.

References

Hoeben B, Bussink J, Troost E, Oyen W, Kaanders J . Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta Oncol. 2013; 52(7):1257-71. DOI: 10.3109/0284186X.2013.812799. View

Edwards R, Greenwood H, McRobbie G, Khan I, Witney T . Robust and Facile Automated Radiosynthesis of [F]FSPG on the GE FASTlab. Mol Imaging Biol. 2021; 23(6):854-864. PMC: 8578107. DOI: 10.1007/s11307-021-01609-w. View

Smith L, Greenwood H, Tyrrell W, Edwards R, De Santis V, Baark F . The chicken chorioallantoic membrane as a low-cost, high-throughput model for cancer imaging. Npj Imaging. 2024; 1:1. PMC: 7615542. DOI: 10.1038/s44303-023-00001-3. View

Pigorsch S, Wilkens J, Kampfer S, Kehl V, Hapfelmeier A, Schlager C . Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. Radiat Oncol. 2017; 12(1):45. PMC: 5333380. DOI: 10.1186/s13014-017-0776-1. View

Overgaard J . Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. Radiother Oncol. 2011; 100(1):22-32. DOI: 10.1016/j.radonc.2011.03.004. View

Sharkey A, Witney T, Cook G . Is System x a Suitable Target for Tumour Detection and Response Assessment with Imaging?. Cancers (Basel). 2023; 15(23). PMC: 10705217. DOI: 10.3390/cancers15235573. View

Strojan P, Hutcheson K, Eisbruch A, Beitler J, Langendijk J, Lee A . Treatment of late sequelae after radiotherapy for head and neck cancer. Cancer Treat Rev. 2017; 59:79-92. PMC: 5902026. DOI: 10.1016/j.ctrv.2017.07.003. View

Huang J, Chunta J, Amin M, Lee D, Grills I, Wong C . Early treatment response monitoring using 2-deoxy-2-[ 18F]fluoro-D-glucose positron emission tomography imaging during fractionated radiotherapy of head neck cancer xenografts. Biomed Res Int. 2014; 2014:598052. PMC: 4022256. DOI: 10.1155/2014/598052. View

Greenwood H, Edwards R, Koglin N, Berndt M, Baark F, Kim J . Radiotracer stereochemistry affects substrate affinity and kinetics for improved imaging of system x in tumors. Theranostics. 2022; 12(4):1921-1936. PMC: 8825600. DOI: 10.7150/thno.63237. View

10.

Eschmann S, Paulsen F, Bedeshem C, Machulla H, Hehr T, Bamberg M . Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007; 83(3):406-10. DOI: 10.1016/j.radonc.2007.05.014. View

11.

Zschaeck S, Lock S, Hofheinz F, Zips D, Mortensen L, Zophel K . Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. Radiother Oncol. 2020; 149:189-196. DOI: 10.1016/j.radonc.2020.05.022. View

12.

Wee J, Anderson B, Corry J, DCruz A, Soo K, Qian C . Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009; 10(11):1086-92. DOI: 10.1016/S1470-2045(09)70266-9. View

13.

Isles M, McConkey C, Mehanna H . A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008; 33(3):210-22. DOI: 10.1111/j.1749-4486.2008.01688.x. View

14.

McCormick P, Greenwood H, Glaser M, Maddocks O, Gendron T, Sander K . Assessment of Tumor Redox Status through ()-4-(3-[F]fluoropropyl)-L-Glutamic Acid PET Imaging of System x Activity. Cancer Res. 2018; 79(4):853-863. PMC: 6379064. DOI: 10.1158/0008-5472.CAN-18-2634. View

15.

Bae S, Wang J, Georgiou D, Wen X, Cohen A, Geng L . Feasibility of [F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type Colorectal Cancer. Tomography. 2023; 9(2):497-508. PMC: 10037609. DOI: 10.3390/tomography9020041. View

16.

Troost E, Vogel W, Merkx M, Slootweg P, Marres H, Peeters W . 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007; 48(5):726-35. DOI: 10.2967/jnumed.106.037473. View

17.

Mortensen L, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P . FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012; 105(1):14-20. DOI: 10.1016/j.radonc.2012.09.015. View

18.

Dolezel M, Slavik M, Blazek T, Kazda T, Koranda P, Veverkova L . FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer. J Pers Med. 2022; 12(8). PMC: 9410424. DOI: 10.3390/jpm12081245. View

19.

Sabharwal S, Schumacker P . Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?. Nat Rev Cancer. 2014; 14(11):709-21. PMC: 4657553. DOI: 10.1038/nrc3803. View

20.

Witney T, James M, Shen B, Chang E, Pohling C, Arksey N . PET imaging of tumor glycolysis downstream of hexokinase through noninvasive measurement of pyruvate kinase M2. Sci Transl Med. 2015; 7(310):310ra169. DOI: 10.1126/scitranslmed.aac6117. View